Drugs / recombinant human platelet derived growth factor
recombinant human platelet derived growth factor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05442034 | Jan 2023 → Jun 2027 expected | periodontal disorder | Nova Southeastern University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human platelet derived growth factor | “recombinant human platelet derived growth factor (rh-PDGF) in combination with bone allograft” NCT05442034 ↗ |
| Known as | GEM21 | “rh-PDGF (test) in its commercial form (GEM21)” NCT05442034 ↗ |
| Known as | rh-PDGF | “recombinant human platelet derived growth factor (rh-PDGF) in combination with bone allograft” NCT05442034 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human platelet derived growth factor is a protein” NCT05442034 ↗ |